127 related articles for article (PubMed ID: 11286132)
21. Expression of matrix metalloproteinases in the microenvironment of spontaneous and experimental melanoma metastases reflects the requirements for tumor formation.
Hofmann UB; Eggert AA; Blass K; Bröcker EB; Becker JC
Cancer Res; 2003 Dec; 63(23):8221-5. PubMed ID: 14678978
[TBL] [Abstract][Full Text] [Related]
22. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer.
Ross JS; Kaur P; Sheehan CE; Fisher HA; Kaufman RA; Kallakury BV
Mod Pathol; 2003 Mar; 16(3):198-205. PubMed ID: 12640098
[TBL] [Abstract][Full Text] [Related]
23. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
24. [Prognostic value of stromal immunolabelling by MMP-2, MT1-MMP and TIMP-2 in clinically localized prostate cancer].
Semaan M; Jovenin N; Birembaut P; Menard J; Staerman F
Prog Urol; 2005 Apr; 15(2):250-4. PubMed ID: 15999602
[TBL] [Abstract][Full Text] [Related]
25. Regulation of matrix metalloproteinase 13 expression by androgen in prostate cancer.
Pang ST; Flores-Morales A; Skoog L; Chuan YC; Nordstedt G; Pousette A
Oncol Rep; 2004 Jun; 11(6):1187-92. PubMed ID: 15138554
[TBL] [Abstract][Full Text] [Related]
26. [Matrix metalloproteinases and colorectal cancer].
Roeb E; Matern S
Med Klin (Munich); 2003 Dec; 98(12):763-70. PubMed ID: 14685678
[TBL] [Abstract][Full Text] [Related]
27. Expression of matrix metalloproteinase (MMP)-7 and MMP-13 and loss of MMP-19 and p16 are associated with malignant progression in chronic wounds.
Impola U; Jeskanen L; Ravanti L; Syrjänen S; Baldursson B; Kähäri VM; Saarialho-Kere U
Br J Dermatol; 2005 Apr; 152(4):720-6. PubMed ID: 15840104
[TBL] [Abstract][Full Text] [Related]
28. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
[TBL] [Abstract][Full Text] [Related]
29. Expression of matrix metalloproiteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in hepatocellular carcinoma tissue, compared with the surrounding non-tumor tissue.
Matsunaga Y; Koda M; Murawaki Y
Res Commun Mol Pathol Pharmacol; 2004; 115-116():143-50. PubMed ID: 17564313
[TBL] [Abstract][Full Text] [Related]
30. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.
Drew AF; Blick TJ; Lafleur MA; Tim EL; Robbie MJ; Rice GE; Quinn MA; Thompson EW
Gynecol Oncol; 2004 Dec; 95(3):437-48. PubMed ID: 15581944
[TBL] [Abstract][Full Text] [Related]
31. Immunohistochemical expression of matrix metalloproteinases 1, 2, and 9 in odontogenic myxoma and dental germ papilla.
Nonaka CF; Augusto Vianna Goulart Filho J; Cristina da Costa Miguel M; Batista de Souza L; Pereira Pinto L
Pathol Res Pract; 2009; 205(7):458-65. PubMed ID: 19243899
[TBL] [Abstract][Full Text] [Related]
32. Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size.
Romanic AM; White RF; Arleth AJ; Ohlstein EH; Barone FC
Stroke; 1998 May; 29(5):1020-30. PubMed ID: 9596253
[TBL] [Abstract][Full Text] [Related]
33. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
34. Relationships between matrix metalloproteinases and tissue inhibitor of metalloproteinases in the wall of abdominal aortic aneurysms.
Nishimura K; Ikebuchi M; Kanaoka Y; Ohgi S; Ueta E; Nanba E; Ito H
Int Angiol; 2003 Sep; 22(3):229-38. PubMed ID: 14612849
[TBL] [Abstract][Full Text] [Related]
35. Association between cyclooxygenase-2 and matrix metalloproteinase-2 expression in non-small cell lung cancer.
Byun JH; Lee MA; Roh SY; Shim BY; Hong SH; Ko YH; Ko SJ; Woo IS; Kang JH; Hong YS; Lee KS; Lee AW; Park GS; Lee KY
Jpn J Clin Oncol; 2006 May; 36(5):263-8. PubMed ID: 16735371
[TBL] [Abstract][Full Text] [Related]
36. Neuropeptides induce Mr 92,000 type IV collagenase (matrix metalloprotease-9) activity in human prostate cancer cell lines.
Sehgal I; Thompson TC
Cancer Res; 1998 Oct; 58(19):4288-91. PubMed ID: 9766654
[TBL] [Abstract][Full Text] [Related]
37. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
38. Expression of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue.
Brehmer B; Biesterfeld S; Jakse G
Prostate Cancer Prostatic Dis; 2003; 6(3):217-22. PubMed ID: 12970724
[TBL] [Abstract][Full Text] [Related]
39. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2.
Kayano K; Shimada T; Shinomiya T; Nakai S; Hisa Y; Aoki T; Seiki M; Okada Y
J Pathol; 2004 Apr; 202(4):403-11. PubMed ID: 15095267
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinases may contribute compensationally to tumor invasion in T1 colorectal carcinomas.
Masaki T; Sugiyama M; Matsuoka H; Abe N; Izumisato Y; Sakamoto A; Atomi Y
Anticancer Res; 2003; 23(5b):4169-73. PubMed ID: 14666620
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
